Elicio in the News
April 6, 2023 ||
Cancer vaccines: 10 biotech companies that have changed the game
LABIOTECH: Elicio Therapeutics specializes in immunotherapeutic research in the field of cancer and infectious diseases. And its amphiphile technology (AMP) platform is the foundation for the various vaccine candidates in its pipeline, against cancer and other diseases. » Read more
January 31, 2023 ||
What do you view as the most disruptive or transformational technology or development on the horizon?
PHARMA'S ALMANAC: I’ve seen two areas within oncology in particular that have grown significantly with revolutionary potential in the coming year: therapeutics targeting KRAS mutations and the re-emergence of cancer vaccines. Christopher Haqq, MD, PhD » Read more
January 17, 2023 ||
Cancer Biotech Elicio Finds Path to Public Markets Via Angion Reverse Merger
MED CITY NEWS: Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes. » Read more
November 9, 2022 ||
Leveraging Lymph Nodes With Elicio’s Dr. Peter DeMuth
Chief Scientific Officer Peter DeMuth, PhD at Elicio HQ in Boston talks about how the platform works, and how it's driving rapid clinical progress for the company's robust pipeline of therapeutic vaccines in oncology. » Read more
September 23, 2022 ||
Cancer Vaccines Push Toward Viability with New Approaches and Targets
BIOSPACE: The advances in immuno-oncology and adaptive cell therapy that began about a decade ago, however, are enabling fresh, biology-driven approaches with the potential to bring therapeutic cancer vaccines much closer to fruition. » Read more
September 20, 2022 ||
Elicio Receives $2.8M Grant for Cancer Vaccine Development
PRECISION ONCOLOGY NEWS: Elicio Therapeutics said Tuesday that it received a $2.8 million grant from the Gastro-Intestinal Research Foundation (GIRF) in Chicago to fund research for two therapeutic cancer vaccines. » Read more
June 4, 2022 ||
Developing Subunit Vaccines Based on an Amphiphile Platform
BIOPROCESS INTERNATIONAL: Subunit vaccines stimulate immune cells by delivering selected components of a pathogen of interest rather than the entire pathogen. Elicio Therapeutics is developing subunit vaccines that target a recipient’s lymph node to elicit a robust immune response. » Read more
May 23, 2022 ||
Elicio Touts “Huge Potential” for Cancer Vaccine Following Preclinical Data
BIOSPACE: Immuno-oncology has grown enormously in the last decade, and the COVID-19 pandemic has accelerated our knowledge of the immune system. Elicio Therapeutics published data on the preprint server, bioRxiv, describing preclinical research on its cancer vaccine that shows a lot of promise. » Read more
May 17, 2022 ||
Elicio inks deal with Regeneron to evaluate ELI-002 in combination with Libtay
THE PHARMA LETTER: USA-based clinical-stage biotech Elicio Therapeutics has entered into a clinical supply agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors. » Read more
May 13, 2022 ||
BioSpace Movers & Shakers: Singular Genomics, Marengo, Ventyx, Caribou and More
BIOSPACE: Building stronger companies requires the right leadership. This week, life sciences companies from across the globe pinpoint the Movers & Shakers who will best benefit their company. » Read more
March 11, 2022 ||
What’s the key to being a leader in the industry?
PHARMA'S ALMANAC: Progress in Therapeutics » Read more
March 11, 2022 ||
What important company milestone do you anticipate reaching in 2022?
PHARMA'S ALMANAC: 2022 Milestones » Read more
March 1, 2022 ||
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
SCRIP: High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease » Read more
January 11, 2022 ||
CEO to CEO: Tips for First-time Founders
BIOSPACE: We picked the brains of 10 biotech CEOs and founders to solicit their advice for first-time founders. Here’s what they told us: » Read more